Evidence map›Paper›PMID 32418174›Full record

Trial reportChinese journal of integrative medicine2021

Effect Evaluation of Strychnos nux-vomica L. with Integrative Methods for Bortezomib-Induced Peripheral Neuropathy in Multiple Myeloma Patients: A Self-Controlled Clinical Trial.

Tie-Ying Dai, Chu-Chu Chen, Li-Li Hong, Hang-Ping Ge, Jun Pei, Wen-Qi Lyu, Xue Yang, Jian-Ping Shen, Zhi-Ping Hu

Abstract readRandomized Controlled Trial
PubMed Publisher
In one paragraph

Trial report in Chinese journal of integrative medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact, top 95% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 5 citations in OpenAlex.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Tie-Ying DaiDepartment of Hematology, The First Hospital Affiliated to Zhejiang University of Traditional Chinese Medicine, Hangzhou, 310006, China.
Chu-Chu ChenDepartment of Hematology, The First Hospital Affiliated to Zhejiang University of Traditional Chinese Medicine, Hangzhou, 310006, China.
Li-Li HongDepartment of Hematology, The First Hospital Affiliated to Zhejiang University of Traditional Chinese Medicine, Hangzhou, 310006, China.
Hang-Ping GeDepartment of Hematology, The First Hospital Affiliated to Zhejiang University of Traditional Chinese Medicine, Hangzhou, 310006, China.
Jun PeiDepartment of Hematology, The First Hospital Affiliated to Zhejiang University of Traditional Chinese Medicine, Hangzhou, 310006, China.
Wen-Qi LyuDepartment of Hematology, The First Hospital Affiliated to Zhejiang University of Traditional Chinese Medicine, Hangzhou, 310006, China.
Xue YangDepartment of Hematology, The First Hospital Affiliated to Zhejiang University of Traditional Chinese Medicine, Hangzhou, 310006, China.
Jian-Ping ShenDepartment of Hematology, The First Hospital Affiliated to Zhejiang University of Traditional Chinese Medicine, Hangzhou, 310006, China.
Zhi-Ping HuDepartment of Hematology, The First Hospital Affiliated to Zhejiang University of Traditional Chinese Medicine, Hangzhou, 310006, China. hzpzy@163.com.
Zhejiang University · CNZhejiang Chinese Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveTo explore the clinical effect and adverse reactions of Strychnos nux-vomica in bortezomib-induced peripheral neuropathy (BIPN) of patients with multiple myeloma (MM).

methodsA total of 19 MM patients with BIPN were enrolled and Nux Vomica Capsule (NVC, 0.4 g, thrice daily) were orally administrated for 30 days. Comparative analysis on parameters between pre- and post-therapy, including peripheral neuropathy (PN) grade, neurotoxicity score, Chinese medicine (CM) syndrome score, total neuropathy score (TNS), coagulation function, and serum nerve growth factor (NGF) levels were conducted. The adverse events were monitored.

resultsIn BIPN of MM patients who received NVC, PN grade was lowered, neurotoxicity score was obviously decreased (P⩽0.01), and both CM syndrome score and TNS were remarkably decreased (P<0.01). After the therapy, activated partial thromboplastin time was prolonged (P<0.01) and fibrinogen was declined (P<0.05), showing improvement in the hypercoagulable state of patients. No significant difference of NGF recovery degrees was detected between pre- and post-therapy (P>0.05). No evident adverse reactions were observed during the course of treatment.

conclusionStrychnos nux-vomica L. has significantly effect with a good safety in treatment of BIPN in MM patients.

Indexed as

Multiple MyelomaPeripheral Nervous System DiseasesStrychnos nux-vomicaBortezomibHumansSeedsBortezomibbortezomib-induced peripheral neuropathyChinese medicine syndrome scoregrilled nux vomicanerve growth factortotal neuropathy score

Identifiers

PMID32418174
OpenAlexW3025874185

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.